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Background: Malaria is a major public health problem in Nepal inflicted primarily by the parasite Plasmodium vivax, -
the only species responsible for relapse cases in Nepal. Knowledge on its relapse rate is important for successful malaria
control, but is lacking in Nepal. The information on circulating predominant genotypes of P. vivax is equally relevant for
high endemic districts of Nepal to understand the transmission dynamics of the parasite and to uncover the coverage
and efficacy of potential vaccine beforehand.
Methods: A prospective observational study with a six months follow-up period was conducted from August 2010 to
May 2011 in four health centres of Kailali and Kanchanpur districts of Nepal to access the relapse/re-infection rate of
P. vivax. The prevalence and heterogeneity of its genotypes were identified by PCR-RFLP assay targeting central repeat
region of circumsporozoite protein (Pvcsp).
Results: In total, 137 cases microscopically suspected to have P. vivax infection were enrolled in the study. Of these, 23
cases (17%) were detected for the relapse/ re-infection-during a six-month period, with a high proportion being male
cases of age group 11–20 years. For genotyping, 100 whole blood samples were analysed, of which 95% of the parasite
isolates were found to be of VK210 genotype. The minor genotype VK247 existed either in isolation or as mixed
infection with VK210 in rest of the samples.
Conclusions: The relapse/re-infection rate of 17% was determined for P. vivax in Kailali and Kanchanpur districts of
Nepal. A heterogeneous Pvcsp genotypic distribution of P. vivax was detected with VK210 being a predominant type,
suggesting a complex transmission dynamics of the parasite. Expanding such study in other endemic regions of Nepal
would help provide a complete picture on relapse/re-infection rate and parasite genotypic variability that can help in
effective control and management of malaria in Nepal.
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In Nepal, 22.5 million people still live in malaria-prone
areas with 65 of 75 districts considered endemic to the dis-
ease [1]. Malaria control has been identified as priority-I
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distribution, and reproduction in any medium2010–2015 [2]. In Nepal, Plasmodium vivax is respon-
sible for most of disease burden, with 75 to 80% of
reported malaria cases being accounted by this species of
the parasite [2]. It is also the only species in Nepal respon-
sible for leading to relapses. It is co-endemic with Plasmo-
dium falciparum in high-endemic districts [1]. Since
mortality due to P. vivax is lower compared to P. falcip-
arum, the former species has been relatively neglected
and, therefore, largely under-researched [3]. Controlling
vector-borne diseases, such as malaria, is a challenge fortral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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possibility of relapse infections exhibited in the cases
of P. vivax is a barrier to successful treatment and con-
trol of malaria. Thus, determining relapse pattern is
an indispensible component for early management of
vivax malaria.
The neighbouring cities of Indian states are not only
the hub of employment for Nepalis, especially those res-
iding near the border, but are also the source of infec-
tious diseases. A significant proportion of malaria in the
eastern region of Nepal and all other bordering districts
is considered to be imported from border cities of India
[4]. Since malarial epidemiology varies considerably be-
tween different geographic regions as a result of com-
plex interplay among humans and vectors, such porous
borders impose a significant contribution in affecting
the genetic complexity of the parasite. The knowledge
on genotypes of malarial parasites contributes greatly to
our understanding of the dynamics of disease transmis-
sion because studies have shown probable difference in
the choice of preferred Anopheles species as a vector by
various genotypes of P. vivax [5]. Genotyping of P. vivax
species can also help differentiate between a new infec-
tion and a relapsed one, which can play an important
role in controlling the disease [6]. Since several antigens
expressed on the surface of the parasite or on infected hu-
man blood or liver cells strongly illicit the host immune
system, any genetic polymorphisms in these antigens play
a critical role in evading protective immune responses
thereby hindering the development of an effective vaccine
against any Plasmodium species [7]. Thus, understanding
the genetic diversity of potent surface antigens of P. vivax
from various endemic geographic regions across the world
is important in providing crucial data for development of
an effective vaccine [8].
Circumsporozoite protein (Pvcsp) is an abundant
surface antigen of P. vivax sporozoites. The gene en-
coding this protein contains a central region composed
of one of the two types of nona-peptide repeat units,
based on which, the parasite has been divided into two
genotypic variants. The variants with one of the repeat
units GDRA(A/D)GQPA, that is restriction digested by
the enzyme AluI is referred to as VK210 genotype
while those with the other repeat unit ANGA(G/D)(N/
D)QPG, that is restricted by BstNI is recognized as
VK247 type [9-12]. Studies have showed differential
geographical distribution and probable differences in
transmission intensity, vector selection, drug resistance
and treatment responses existing in these genotypes
[13-16].
Since no Pvcsp-based genotyping studies have been
carried out before in Nepal, this study aims to provide a
pilot data on Pvcsp genotypes circulating in Kailali and
Kanchanpur districts for Nepal.Methods
Relapse/re-infection study
A prospective observational study was carried out in
four health centres of Kailali and Kanchanpur districts
of far-west Nepal from August 2010 to May 2011. These
districts are among high malaria endemic districts of
Nepal. As per the 2010 annual report of Department of
Health Services, Government of Nepal, the annual para-
site incidence rate per 1,000 population was 1.77% for
Kailali and 0.6% for Kanchanpur ,while that for the en-
tire nation was just 0.16% in the year 2010.
After taking an informed consent from malaria-
suspected symptomatic patients and performing their
initial clinical examination, the blood samples were col-
lected for thick blood film microscopic examination.
The parasitological examination was done independ-
ently by two trained laboratory technicians and the
slides were sent to an independent laboratory for quality
assurance. All febrile patients positive for P. vivax in
microscopy at the time of visit and confirming to be
able to come on stipulated follow-up visits were consid-
ered eligible and were enrolled in the study. Any of the
cases failing to show the microscopic evidence of
P. vivax or showing mixed or isolated infection with
P. falciparum or presenting any feature of severe mal-
aria or any other underlying chronic severe illness were
excluded from the study. Pregnant women and lactating
mothers were also excluded from the study.
The P. vivax-confirmed enrolled cases were asked to
complete the three-day 25 mg/kg body weight of
chloroquine therapy. The national anti-malarial treat-
ment guidelines of Nepal suggested the combined use
of three-day chloroquine and 14-day primaquine for all
P. vivax confirmed cases. However, the actual trend
practiced in the selected study area was to provide
chloroquine monotherapy to all cases of clinical and
P. vivax malaria. The chloroquine-primaquine therapy
was administered only in the cases who returned to the
centre with renewed symptoms of malaria and further
microscopic evidence of P. vivax.
The first dosage of chloroquine was administered
under direct observation of the research team on the
day when the participant was first enrolled in the study.
The second and third dosages were prescribed for home
use with a detail instruction on the drug regimen and
follow up and with a proper education on the import-
ance of doing so.
The cases were advised to come for follow-up visits on
the third day and at the sixth month of enrolment or on
any day/s when the patient felt febrile. The cases were
rigorously reminded for follow up visits by regular tele-
phone calls. When required, home visits were also done
by the trained and locally mobilized community field
team. An absolute treatment compliance was assumed
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stipulated follow up days.
Because the selected study areas had high P. vivax in-
cidence rate, the chances of re-infection at any point
after the completion of chloroquine therapy could not
be ignored. Thus, all recurrences were assumed to be ei-
ther because of relapses or re-infections. And because
the study areas had rare history of treatment failure for
P. vivax chloroquine therapy, the recrudescence was as-
sumed to be unlikely.
Due to the logistical and financial constrains, the cases
could be followed up for a period of six months only. On
each follow-up day, thick blood film examination was car-
ried out. Those febrile patients who returned the centre
after one month of the start of chloroquine therapy and
were microscopically found to be positive for P. vivax
were considered relapse/re-infection cases whose rate was
determined by dividing the number of such recurred cases
by total number of P. vivax confirmed cases treated with
standard chloroquine regimen. The cases presenting with
recurrences and the remainder of enrolled cases who com-
pleted six months of follow up were given primaquine
therapy in the dosage of 7.5 mg twice a day for 14 days
after screening for G6PD deficiency.
Genotyping study
Parasite DNA was extracted from whole blood samples
using commercial DNA extraction kit (QiagenDNeasy
Blood & Tissue Kit). Before processing for genotyping
assay, all microscopically detected samples were con-
firmed for the presence of P. vivax by two rounds of
nested PCR targeting ssrRNA [17]. Plasmodium vivax
confirmed samples were genotyped by nested PCR-RFLP
assay based on central repeat region of Pvcsp gene as
mentioned by Imwong et al. [18]. Briefly PCR reaction
was set with 800 nM dNTPs, 1 mM MgCl2, 0.4 unit Taq
polymerase, 400 nM of each primers with 1 μl of DNA
template for first round and 1 μl of first round PCR prod-
uct as template for second round nested PCR. The
thermocycling condition for first round PCR was 95°C for
5 min followed by 25 cycles of 58°C for 2 min, 72°C for
2 min and 94°C for 1 min, and one cycle of each 58°C
for 2 min and 72°C for 5 min. That for second nested PCR
was exactly the same as for first round except that
annealing was at 62°C for 2 min and with 30 cycles. The
second round products were digested by restriction en-
zymes AluI and BstNI in parallel set of tubes and visual-
ized in 2% agarose gel to distinguish between two
genotypes of P. vivax on the basis of susceptibility to di-
gestion by any one of the enzymes. Broader Pvcsp geno-
types of P. vivax isolates were further attempted to
subdivide into finer Pvcsp allelic types utilizing fragment
size heterogeneity of PCR products and sequence varia-
tions in pre- and post-repeat regions by PCR-RFLPprotocol followed by 3% agarose gel electrophoresis as
mentioned by Imwong et al. [18].Ethical approval
This study was initiated by Nepal Health Research
Council (NHRC), with documented approval from its
Ethical Review Board (ERB).Results
Relapse/re-infection assessment
Among malaria-suspected patients visiting four selected
health centres, a total of 137 cases were microscopically
observed for P. vivax infection and fulfilled other inclu-
sion criteria. Age distribution of these cases varied from
15 to 83 years. The highest percentage of cases affected
belonged to the productive age group of 21 to 30 years
(35.7%) followed by 11 to 20 years (27%) (Figure 1). The
number of male cases affected was much higher (81%)
than that of female cases. Out of 137 total cases en-
rolled, recurrence was reported among 23 cases (17%).
A high percentage (47.8%) of relapse/re-infection oc-
curred among young people of age group of 11 to
20 years (Figure 1) and among male patients (91.3%).
However this recurrence rate difference by gender could
not be considered significant because the initial number
of male cases studied was much greater than that of fe-
male cases.
All of the 23 cases of the first reported recurrences oc-
curred after one month of primary detection of the para-
site. During a six-month follow-up period, most (56.56%)
recurrences were reported only once. The remainder of
the recurrences were reported for multiple number of
times ranging from twice to five times despite the possible
completion of 14-day unobserved primaquine therapy.Genotype assessment
Molecular analysis could be carried out in only 100 ran-
domly selected blood samples. All of these samples were
positive for P. vivax in two separate rounds of nested
PCR. Among all samples tested, 95% of P. vivax parasites
were found to be of VK210 genotype in PCR-RFLP based
Pvcsp molecular genotyping assay. The remainder (5%) of
the isolates belonged to VK247 type, 40% of which existed
as mixed infection with VK210. Figure 2 shows represen-
tative agarose gel image of restriction digestion of Pvcsp
gene for genotyping test.
Allelic variations of each VK210 and VK247 isolates
could not be distinguished either based on fragment
size variation of PCR products or PCR-RFLP based se-
quence variation of pre and post repeat regions when
analysed in 3% agarose gel.
Figure 1 Percentage distribution of primary and recurrent infection cases of Plasmodium vivax among different age groups.
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It has been proposed that in endemic areas, a large pro-
portion of indigenous population harbours latent hyp-
nozoite forms of P. vivax, which can be activated by a
systemic illness such as vivax or falciparum malaria.
This is the reason for observed higher rates of relapse in
people living in endemic areas especially in the pockets
infiltrated with both of these malarial species [19]. The
relapse rate of P. vivax varies considerably across variousFigure 2 Gel picture of PCR RFLP-based Pvcsp genotyping of Plasmod
digestion products for each samples. Samples 29 and 38 each were dig
VK247 and VK210 type, respectively. Sample 45 was digested by both AluIgeographic regions. It also depends on immunity of the
subjects to the disease [19,20]. Such relapses pose sig-
nificant hurdles in an effective control of malaria, par-
ticularly for endemic countries like Nepal. However, in
context of Nepal, negligible research has been conducted
addressing such problems.
Since the two districts chosen for this study had high in-
cidence of P. vivax transmission, higher probability of
renewed infection among the enrolled cases could beium vivax for samples 29, 38 and 45; a and b are AluI and BstNI
ested by BstNI and AluI only, respectively, suggesting them to be of
and BstNI, suggesting it to be a mixed infection.
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quine therapy in a developing country settings. Due to
the nature of the study, re-infections could not be dif-
ferentiated from relapses in this study and as such all
recurrences were unequivocally considered as either re-
lapse or re-infection. However, because primaquine was
excluded initially for the treatment of P. vivax con-
firmed enrolled cases, it is highly probable that majority
of recurrences were due to relapses.
In this study, a stringent follow up schedule had been
practiced ensuring an absolute adherence to chloroquine
treatment. Further, all study subjects were observed to
respond well to the therapy thereby excluding any inci-
dences of treatment failure. Moreover because all first
time reported recurrences occurred after 28 days of pri-
mary detection and completion of standard chloroquine
therapy, the possibility of recrudescence could be ex-
cluded in this study.
During six months’ follow-up, a relapse/re-infection rate
of 17% was detected. Variable recurrence rates of P. vivax
has been recorded across the globe. In India, prospective
studies carried out over the past 25 years have recorded
post-chloroquine anti-malarial treatment recurrence rates
to vary between 8.6% (Orissa), 8.9% (Madhya Pradesh)
[19], 12.6% (Mumbai) [21] and 40% (Delhi) [22]. Variable
latency period among P. vivax phenotypes has been de-
scribed [19,23]. A study in Delhi, India has observed a dis-
tinct rise in percentage of relapse cases as the follow-up
period increased from one year (23.3%) to five years
(44.3%) [22]. These findings suggest that determination of
an actual relapse rate relies greatly on the duration of fol-
low up. Taking this into consideration, for the follow-up
period being less than a year, the relapse/re-infection rate
of 17% observed in this study might probably be
underestimated. Further, because there might possibly be
many asymptomatic self- limiting relapse/re-infection
cases that might have gone unreported and thus failed be-
ing recaptured, the true relapse/re-infection rate might
have been higher than observed here.
A high percentage of relapse/reinfection was recorded
among young people of age group 11 to 20 years which
appeared to decrease with increasing age. This corrobo-
rates with literature findings that some degree of immun-
ity is gained by early adulthood in indigenous population
living in endemic areas, thereby reducing the number of
relapses in increasing age groups [19].
In this study, a 14-day standard primaquine therapy
was prescribed for all confirmed recurrence cases. How-
ever, many cases repeatedly suffered further episodes of
recurrences, ranging from twice to as many as five times
within a half-year period from primary infection. This
suggested that the prescribed primaquine regimen as per
the WHO recommendations [24] possibly was not abso-
lutely efficient for preventing all relapses. This kind oftherapeutic response variability and inadequacy has also
been observed in many endemic regions [20,25,26]. How-
ever, it must be pointed out that, since the primaquine
treatment provided to study subjects was an unmonitored
14-day course, an absolute compliance cannot be assured.
Further, many of the recurrences might have been due to
the renewed infection by blood stage parasites, against
which the primaquine has reduced effect.
Regarding the circumsporozoite genotyping, VK210
genotype was found to be the most predominant genotype
constituting 95% of parasite isolates. Though global preva-
lence of individual genotypes varies geographically, such
prepotency of the VK210 genotype of P. vivax has been a
common worldwide occurrence [27,28]. A similar study
carried out in Pakistan showed results almost identical to
this study - reporting isolation of 95.7% of VK210, 2.7% of
VK247 and 1.6% of mixed genotypes. Such VK210 pre-
dominance has been reported in other malaria-endemic
countries such as Myanmar (66%), Thailand (77%), Brazil
(86%), Kolkata (India) (99.3%) Azerbaijan (100%) and
Honduras (100%) [5,8,13,29-31]. This is in contrast to the
findings of some studies reporting the predominance of
VK247 genotype [32-34]. Such differences in prevalence of
a different variant of parasite could be due to the predom-
inance of different species and strain of Anopheles mos-
quito vector that is more susceptible to VK247 genotype as
mentioned in several studies [14]. One study in southern
Mexico [35] showed that Anopheles albimanus was more
susceptible to infections by the VK210 subtype, while
Anopheles pseudopunctipennis was more susceptible to
VK247. However, in context of Nepal, out of 42 Anopheles
species found, only three species, Anopheles fluviatilis,
Anopheles maculates and Anopheles annularis have been
identified as vectors of malaria [2]. This suggests that there
might exist a unique dynamic interaction among existing
P. vivax genotypes and Nepali strains of Anopheles vectors,
thereby warranting further studies to verify this hypothesis.
Allelic variation of each of VK210 and VK247 based
on number of repeats of central motif of Pvcsp gene and
thus differences in size of PCR products could not be
detected as previously observed [11,25] either because
the 3% agarose gel was not sufficient enough to resolve
the existing fragment length variations, or isolates in this
study lacked this variation. Further, PCR-RFLP analysis
of the isolates based on pre- and post repeats adjoining
the central repeat region could not be determined when
restriction-digested products were run in 3% agarose gel
probably because of the same above reasons. Use of ca-
pillary electrophoresis might have provided enough reso-
lution to identify these minor fragment length variations.
Conclusion
In conclusion, P. vivax relapse/re-infection rate of 17%
was observed during a brief follow up of six months,
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vided the follow up were to extend. This contributes a
significant hurdle in effective control of malaria in Nepal
and challenges its ambitious goal to see a malaria-free
country by 2026.
Since this is the first-ever Pvcsp marker-based genotyp-
ing study carried out in Nepal, predominance of VK210
genotype can be considered as a primary information on
Pvcsp genotype for Nepal. Further, as this study involved
only two out of 65 malaria-endemic districts of Nepal, a
larger representative study is warranted to provide further
evidence on the type(s) and distribution of the prevailing
Pvcsp genotypes of P. vivax.
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